Dans cette déclaration de consensus datée du 28 avril 2022, le Conseil HPV du CHIC accueille favorablement la conclusion du SAGE de l’OMS selon laquelle un vaccin anti-papillomavirus à dose unique confère une protection solide, comparable à un schéma à deux ou trois doses, et appelle les programmes nationaux de vaccination et les organes consultatifs […]
Topic: Single Dose Evidence
CHIC HPV Council Consensus Statement on One-Dose Recommendation
In this consensus statement dated April 28, 2022, the CHIC HPV Council welcomes the WHO SAGE conclusion that a single-dose HPV vaccine delivers solid protection comparable to two- or three-dose schedules, and urges national immunization programmes and policy bodies to act on this recommendation. The Council highlights benefits for girls and families (comparable protection), programme […]
Evidence for an HPV one-dose schedule
In this review, Stanley and colleagues examine the biological plausibility and clinical trial evidence supporting a single-dose HPV vaccination schedule. The authors synthesize data from randomized controlled trials—including KEN SHE (Kenya), DoRIS (Tanzania), the Costa Rica Vaccine Trial, and the IARC India trial—demonstrating high and durable efficacy comparable to multi-dose regimens. Post-licensure observational studies and […]
Policy, Schedule and Vaccine Product Choice: Q&A Session
The Q&A session highlighted critical considerations for transitioning to single-dose HPV vaccination, including evidence needs for NITAG decision-making, updates on ongoing trials like HANDS, and the unique immunological advantages of virus-like particle vaccines. Participants raised concerns about vaccine efficacy in older adolescents, genotype distribution differences (e.g., HPV 52 prevalence), and implications for vaccine selection. Discussions […]
Single-dose scientific evidence data and implementation progress
The session reviewed global evidence underpinning the WHO’s 2022 recommendation for single-dose HPV vaccination. Data from pivotal trials in Costa Rica, India, and Kenya demonstrated sustained efficacy exceeding 80–90% against HPV 16/18 infection for over a decade. Immunogenicity studies confirmed durable antibody responses comparable to multi-dose schedules, with similar outcomes in boys and girls. Population-level […]
Le vaccin à dose unique contre le VPH : une opportunité pour accélérer l’élimination du cancer du col de l’utérus en Afrique subsaharienne
Ce poster analyse le potentiel du schéma vaccinal à dose unique pour surmonter les obstacles économiques et logistiques liés à l’introduction du vaccin HPV en Afrique subsaharienne. Une revue de littérature (2017–2023) montre que la dose unique offre une protection comparable aux schémas à deux ou trois doses. Cette approche simplifiée pourrait réduire les coûts, […]
Aperçu des données probantes sur l’administration d’une dose unique
Cette présentation examine les données mondiales sur la vaccination anti-HPV à dose unique, compilées par le Consortium d’évaluation du vaccin à dose unique et financées par la Fondation Bill & Melinda Gates. Elle met en avant des essais cliniques menés en Afrique, Asie et Amérique latine montrant une efficacité comparable entre les schémas à dose […]
Overview of single-dose evidence
This presentation reviews global evidence on single-dose HPV vaccination compiled by the Single-Dose HPV Vaccine Evaluation Consortium, funded by the Bill & Melinda Gates Foundation. It highlights clinical trial data from Africa, Asia, and Latin America showing comparable efficacy between single- and multi-dose schedules in preventing HPV 16/18 infections for at least ten years. WHO’s […]
DoRIS Trial
Single-dose HPV vaccination in Tanzanian girls (9–14 years) achieved >98% seropositivity for HPV‑16/18 at 36 months. Antibody levels plateaued after 12 months and remained stable through 36 months, comparable to multi‑dose regimens. Avidity indices were similar across one‑, two‑, and three‑dose groups, indicating strong binding responses. Immunobridging showed single‑dose responses were non‑inferior to efficacy trials […]
Update on one dose trial data findings – Q&A Session
The panel reviewed evidence from multiple single-dose HPV vaccine studies, including India IARC, Costa Rica, Doris, and Kenshe trials. Observational and randomized data consistently show robust, durable immune responses and high efficacy of single-dose schedules, particularly against HPV 16/18. Immune responses remain stable over a decade, comparable to two- or three-dose regimens. Ongoing studies (Escudo, […]